Expression und Immunogenität des tumorassoziierten Antigens G250 (Carboanhydrase IX, MN 75) bei Patienten mit Plattenepithelkarzinom des Kopf- und Hals-Bereichs
LizenzStandard (Fassung vom 01.10.2008)
Despite advances in surgery, radio-and chemotherapy, therapeutic approaches for patients with head and neck squamous carcinoma (HNSCC) need to be improved. Immunotherapies might constitute novel treatment options. We therefore investigated the expression and immuonogenicity of the tumor-associated antigen (TAA) G250 in HNSCC patients. 22 HNSCC samples were examined for the expression of G250 by western blotting and immunohistochemistry. For 7/22 mixed lymphocyte peptide cultures (MLPC) were performed to evaluate the frequencies of cytotoxic T cells specifically recognizing G250 using Tetramer staining and and enzyme linked immunospot assay. G250 was expressed in 80% of the HNSCC samples at protein level. In 4/8 patients 0,04-0,10% of CD8+ effector T cells recognized Tetramers for G250 and secreted INF-y and granzyme B in ELISPOT assays. G250 is expressed at high frequency in HNSCC and recognized by cytotoxic CD8+ effector T cells. Therefore G250 is an interesting target for T cell based immunotherapies for HNSCC.
Erstellung / Fertigstellung
Normierte SchlagwörterPlattenepithelcarcinom [GND]
Head and neck squamous carcinoma [MeSH]